Zafgen evaluating strategic options  Metabolic company Zafgen Inc. (NASDAQ:ZFGN) has retained advisory firm MTS Health Partners to explore strategic alternatives after receiving new preclinical data that the company believes will be insufficient for FDA to...

FDA approves Samsung's Humira biosimilar  Samsung Bioepis Co. Ltd. (Incheon, South Korea) said FDA approved Hadlima adalimumab-bwwd, a biosimilar of autoimmune drug Humira from AbbVie Inc. (NYSE:ABBV). Samsung's partner Merck & Co. Inc. (NYSE:MRK) will...

Zafgen lost $1.10 (24%) to $3.50 in after-hours trading Monday after the company said it suspended plans to submit an IND for Prader-Willi syndrome candidate ZGN-1258 based on findings of muscle degeneration and other anomalies...

Zafgen Inc. (NASDAQ:ZFGN) said the 1.8 mg subcutaneous dose of ZGN-1061 met primary and secondary endpoints in a second dose cohort from a Phase II trial to treat Type II diabetes. The adverse event profile...

Zafgen Inc. (NASDAQ:ZFGN) shares fell $3.69 (41%) to $5.41 Nov. 26 after it disclosed that FDA placed a clinical hold on an IND for ZGN-1061 to treat Type II diabetes. Zafgen said the agency cited...

Zafgen Inc. (NASDAQ:ZFGN) shares fell $3.69 (41%) to $5.41 Monday after it disclosed that FDA placed a clinical hold on an IND for ZGN-1061 to treat Type II diabetes. Zafgen said the agency cited a...

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million on June 28. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering...

Zafgen Inc. (NASDAQ:ZFGN) said the 0.9 mg dose of subcutaneous ZGN-1061 every three days met the primary endpoint in a Phase II trial to treat Type II diabetes in patients failing multiple other antidiabetic agents....

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million Thursday. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten by...

Asieris Pharmaceuticals Co. Ltd. (Taizhou, China) said on Dec. 27, 2017, that it raised RMB110-RMB120 million ($16.8-$18.3 million) in a series B round led by Lapam Capital. Fellow new investors Kaitai Capital and Zhongguancun Qihang...